Effect of azithromycin on incidence of acute respiratory exacerbations in children with HIV taking antiretroviral therapy and co-morbid chronic lung disease: a secondary analysis of the BREATHE trial

Amy Price; Grace McHugh; Victoria Simms; Robina Semphere; Lucky Gift Chiwiya Ngwira; Tsitsi Bandason; Hilda Mujuru; Jon O. Odland; Rashida A. Ferrand; Andrea M. Rehman

doi:10.1016/j.eclinm.2021.101195

Effect of azithromycin on incidence of acute respiratory exacerbations in children with HIV taking antiretroviral therapy and co-morbid chronic lung disease: a secondary analysis of the BREATHE trial

Amy Price, Grace McHugh, Victoria Simms, Robina Semphere, Lucky Gift Chiwiya Ngwira, Tsitsi Bandason, Hilda Mujuru, Jon O. Odland, Rashida A. Ferrand, Andrea M. Rehman

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Background: In the BREATHE trial weekly azithromycin decreased the rate of acute respiratory exacerbations (AREs) compared to placebo among children and adolescents with HIV-associated chronic lung disease (CLD) taking antiretroviral therapy (ART). The aim of this analysis was to identify risk factors associated with AREs and mediators of the effect of azithromycin on AREs.

Methods: The primary outcome of this analysis was the rate of AREs by study arm up to 49 weeks. We analysed rates using Poisson regression with random intercepts. Interaction terms were fitted for potential effect modifiers.

Findings: We analysed data from 345 participants (171 allocated to azithromycin and 174 allocated to placebo). In the placebo arm, the rate of AREs were higher among those with an abnormally high respiratory rate at baseline (adjusted rate ratio (aRR) 2.90 95% CI 1.30-6.46 p-value 0.0068) and among those with a CD4 cell count <200 cells/mm3 (aRR 2.50; 95%CI 1.04-5.97; p-value 0.0387). We found some evidence for heterogeneity in the effect of azithromycin by sex (p-value for interaction=0.0660); males had a greater reduction in the rate of ARE with azithromycin treatment compared to females. There was weak evidence of azithromycin having a greater impact on reducing AREs in participants with chronic respiratory symptoms at baseline, those on 1st line ART, with a FEV1 score >-2 and participants without baseline resistance to azithromycin.

Interpretation: These may represent subgroups who may benefit the most from treatment with weekly azithromycin

Funding: Global Health and Vaccination Programme of the Norwegian Research Council.

Original language	English
Article number	101195
Journal	eClinicalMedicine
Volume	42
Early online date	12 Nov 2021
DOIs	https://doi.org/10.1016/j.eclinm.2021.101195
Publication status	Published - 1 Dec 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eclinm.2021.101195Licence: CC BY

Azithromycin and AREs- April 2021-Lancet Resp vs LGNAccepted author manuscript, 483 KBLicence: CC BY

Cite this

Price, A., McHugh, G., Simms, V., Semphere, R., Ngwira, L. G. C., Bandason, T., Mujuru, H., Odland, J. O., Ferrand, R. A., & Rehman, A. M. (2021). Effect of azithromycin on incidence of acute respiratory exacerbations in children with HIV taking antiretroviral therapy and co-morbid chronic lung disease: a secondary analysis of the BREATHE trial. eClinicalMedicine, 42, Article 101195. https://doi.org/10.1016/j.eclinm.2021.101195

@article{20578e776d894e068918490176017f13,

title = "Effect of azithromycin on incidence of acute respiratory exacerbations in children with HIV taking antiretroviral therapy and co-morbid chronic lung disease: a secondary analysis of the BREATHE trial",

abstract = "Background: In the BREATHE trial weekly azithromycin decreased the rate of acute respiratory exacerbations (AREs) compared to placebo among children and adolescents with HIV-associated chronic lung disease (CLD) taking antiretroviral therapy (ART). The aim of this analysis was to identify risk factors associated with AREs and mediators of the effect of azithromycin on AREs.Methods: The primary outcome of this analysis was the rate of AREs by study arm up to 49 weeks. We analysed rates using Poisson regression with random intercepts. Interaction terms were fitted for potential effect modifiers.Findings: We analysed data from 345 participants (171 allocated to azithromycin and 174 allocated to placebo). In the placebo arm, the rate of AREs were higher among those with an abnormally high respiratory rate at baseline (adjusted rate ratio (aRR) 2.90 95\% CI 1.30-6.46 p-value 0.0068) and among those with a CD4 cell count <200 cells/mm3 (aRR 2.50; 95\%CI 1.04-5.97; p-value 0.0387). We found some evidence for heterogeneity in the effect of azithromycin by sex (p-value for interaction=0.0660); males had a greater reduction in the rate of ARE with azithromycin treatment compared to females. There was weak evidence of azithromycin having a greater impact on reducing AREs in participants with chronic respiratory symptoms at baseline, those on 1st line ART, with a FEV1 score >-2 and participants without baseline resistance to azithromycin.Interpretation: These may represent subgroups who may benefit the most from treatment with weekly azithromycinFunding: Global Health and Vaccination Programme of the Norwegian Research Council.",

author = "Amy Price and Grace McHugh and Victoria Simms and Robina Semphere and Ngwira, \{Lucky Gift Chiwiya\} and Tsitsi Bandason and Hilda Mujuru and Odland, \{Jon O.\} and Ferrand, \{Rashida A.\} and Rehman, \{Andrea M.\}",

year = "2021",

month = dec,

day = "1",

doi = "10.1016/j.eclinm.2021.101195",

language = "English",

volume = "42",

journal = "eClinicalMedicine",

issn = "2589-5370",

publisher = "Elsevier Ltd",

}

Price, A, McHugh, G, Simms, V, Semphere, R, Ngwira, LGC, Bandason, T, Mujuru, H, Odland, JO, Ferrand, RA & Rehman, AM 2021, 'Effect of azithromycin on incidence of acute respiratory exacerbations in children with HIV taking antiretroviral therapy and co-morbid chronic lung disease: a secondary analysis of the BREATHE trial', eClinicalMedicine, vol. 42, 101195. https://doi.org/10.1016/j.eclinm.2021.101195

Effect of azithromycin on incidence of acute respiratory exacerbations in children with HIV taking antiretroviral therapy and co-morbid chronic lung disease: a secondary analysis of the BREATHE trial. / Price, Amy; McHugh, Grace; Simms, Victoria et al.
In: eClinicalMedicine, Vol. 42, 101195, 01.12.2021.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Effect of azithromycin on incidence of acute respiratory exacerbations in children with HIV taking antiretroviral therapy and co-morbid chronic lung disease: a secondary analysis of the BREATHE trial

AU - Price, Amy

AU - McHugh, Grace

AU - Simms, Victoria

AU - Semphere, Robina

AU - Ngwira, Lucky Gift Chiwiya

AU - Bandason, Tsitsi

AU - Mujuru, Hilda

AU - Odland, Jon O.

AU - Ferrand, Rashida A.

AU - Rehman, Andrea M.

PY - 2021/12/1

Y1 - 2021/12/1

N2 - Background: In the BREATHE trial weekly azithromycin decreased the rate of acute respiratory exacerbations (AREs) compared to placebo among children and adolescents with HIV-associated chronic lung disease (CLD) taking antiretroviral therapy (ART). The aim of this analysis was to identify risk factors associated with AREs and mediators of the effect of azithromycin on AREs.Methods: The primary outcome of this analysis was the rate of AREs by study arm up to 49 weeks. We analysed rates using Poisson regression with random intercepts. Interaction terms were fitted for potential effect modifiers.Findings: We analysed data from 345 participants (171 allocated to azithromycin and 174 allocated to placebo). In the placebo arm, the rate of AREs were higher among those with an abnormally high respiratory rate at baseline (adjusted rate ratio (aRR) 2.90 95% CI 1.30-6.46 p-value 0.0068) and among those with a CD4 cell count <200 cells/mm3 (aRR 2.50; 95%CI 1.04-5.97; p-value 0.0387). We found some evidence for heterogeneity in the effect of azithromycin by sex (p-value for interaction=0.0660); males had a greater reduction in the rate of ARE with azithromycin treatment compared to females. There was weak evidence of azithromycin having a greater impact on reducing AREs in participants with chronic respiratory symptoms at baseline, those on 1st line ART, with a FEV1 score >-2 and participants without baseline resistance to azithromycin.Interpretation: These may represent subgroups who may benefit the most from treatment with weekly azithromycinFunding: Global Health and Vaccination Programme of the Norwegian Research Council.

AB - Background: In the BREATHE trial weekly azithromycin decreased the rate of acute respiratory exacerbations (AREs) compared to placebo among children and adolescents with HIV-associated chronic lung disease (CLD) taking antiretroviral therapy (ART). The aim of this analysis was to identify risk factors associated with AREs and mediators of the effect of azithromycin on AREs.Methods: The primary outcome of this analysis was the rate of AREs by study arm up to 49 weeks. We analysed rates using Poisson regression with random intercepts. Interaction terms were fitted for potential effect modifiers.Findings: We analysed data from 345 participants (171 allocated to azithromycin and 174 allocated to placebo). In the placebo arm, the rate of AREs were higher among those with an abnormally high respiratory rate at baseline (adjusted rate ratio (aRR) 2.90 95% CI 1.30-6.46 p-value 0.0068) and among those with a CD4 cell count <200 cells/mm3 (aRR 2.50; 95%CI 1.04-5.97; p-value 0.0387). We found some evidence for heterogeneity in the effect of azithromycin by sex (p-value for interaction=0.0660); males had a greater reduction in the rate of ARE with azithromycin treatment compared to females. There was weak evidence of azithromycin having a greater impact on reducing AREs in participants with chronic respiratory symptoms at baseline, those on 1st line ART, with a FEV1 score >-2 and participants without baseline resistance to azithromycin.Interpretation: These may represent subgroups who may benefit the most from treatment with weekly azithromycinFunding: Global Health and Vaccination Programme of the Norwegian Research Council.

U2 - 10.1016/j.eclinm.2021.101195

DO - 10.1016/j.eclinm.2021.101195

M3 - Article

SN - 2589-5370

VL - 42

JO - eClinicalMedicine

JF - eClinicalMedicine

M1 - 101195

ER -

Effect of azithromycin on incidence of acute respiratory exacerbations in children with HIV taking antiretroviral therapy and co-morbid chronic lung disease: a secondary analysis of the BREATHE trial

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this